Compounds > quinazolines

Page last updated: 2024-08-21

quinazolines and plx4032

quinazolines has been researched along with plx4032 in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	14 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H	1
Goozner, M	1
Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D	1
Lo, RS	1
Burton, L; Chan, E; Fridlyand, J; Koeppen, H; Li, J; Lin, E; Merchant, M; Moffat, J; Neve, R; Peng, J; Penuel, E; Ribas, A; Settleman, J; Sosman, J; Sutherlin, DP; Wang, Y; Wilson, TR; Yan, Y	1
Clarke, PA; Pearl, LH; Polier, S; Prodromou, C; Samant, RS; Workman, P	1
Blanchet, B; Boudou-Rouquette, P; Dupin, N; Goldwasser, F; Mortier, L; Sakji, L; Thomas-Schoemann, A; Vidal, M; Zhen, Y	1
Belani, CP; Joshi, M; Liu, X; Miller, B; Rice, SJ	1
Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT	1
Nishio, K; Togashi, Y	1
Lim, SY; Menzies, AM; Rizos, H	1
Benhuri, B; Chaudhari, SP; Ciccolini, KT; Duran, J; Kim, J; Lacouture, ME; Lucas, AS; Wu, S	1
Cronise, KE; Duval, DL; Gustafson, DL; Hernandez, BG	1
Bobera, J; Dupuy, AJ; Feddersen, CR; Jennings, BM; Mullen, SA; Riordan, JD; Schillo, JL; Stipp, CS; Varzavand, A; Vaughn, HR; Voigt, AP; Wadsworth, LS; Zhu, EY	1

Reviews

3 review(s) available for quinazolines and plx4032

Article	Year
[Kinase inhibitors and their resistance]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib	2015
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 2017, 06-01, Volume: 123, Issue:S11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2017
Incidence and risk of developing photosensitivity with targeted anticancer therapies. Journal of the American Academy of Dermatology, 2019, Volume: 81, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Clinical Trials as Topic; Humans; Incidence; Molecular Targeted Therapy; Neoplasms; Nivolumab; Photosensitivity Disorders; Piperidines; Quinazolines; Risk Assessment; Vemurafenib	2019

Other Studies

11 other study(ies) available for quinazolines and plx4032

Article	Year
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer research, 2012, Feb-01, Volume: 72, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays	2012
Drug approvals 2011: focus on companion diagnostics. Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2 Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib	2012
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, Jan-26, Volume: 483, Issue:7387 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays	2012
Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell research, 2012, Volume: 22, Issue:6 Topics: Animals; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Melanoma; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Sulfonamides; Transplantation, Heterologous; Vemurafenib	2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012, Jul-26, Volume: 487, Issue:7408 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Hepatocyte Growth Factor; Humans; Indoles; Lapatinib; Ligands; Melanoma; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Sulfonamides; Vemurafenib	2012
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nature chemical biology, 2013, Volume: 9, Issue:5 Topics: Adenosine Triphosphate; Binding, Competitive; Cell Cycle Proteins; Chaperonins; HSP90 Heat-Shock Proteins; Indoles; Lapatinib; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Structure-Activity Relationship; Sulfonamides; Vemurafenib	2013
An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, Jun-01, Volume: 928 Topics: Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Indoles; Liquid-Liquid Extraction; Melanoma; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Vemurafenib	2013
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. PloS one, 2015, Volume: 10, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; G1 Phase; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Sulfonamides; Up-Regulation; Vemurafenib	2015
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts. Journal of translational medicine, 2015, Jun-13, Volume: 13 Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays	2015
Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. Molecular pharmacology, 2019, Volume: 96, Issue:1 Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dog Diseases; Dogs; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; HT29 Cells; Humans; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Quinazolines; Urinary Bladder Neoplasms; Vemurafenib	2019
Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma. Cancer research, 2019, Oct-01, Volume: 79, Issue:19 Topics: Antineoplastic Agents; Benzodioxoles; Drug Resistance, Neoplasm; Guanine Nucleotide Exchange Factors; Humans; Melanoma; Melanoma, Cutaneous Malignant; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-vav; Quinazolines; Signal Transduction; Skin Neoplasms; src-Family Kinases; Vemurafenib	2019